STOCK TITAN
  1. Home
  2. News
  3. INMB

INmune Bio Inc - INMB STOCK NEWS

Welcome to our dedicated news page for INmune Bio (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INmune Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INmune Bio's position in the market.

News
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
INmune Bio Inc. announced a $9.7 million Registered Direct Offering priced At-the-Market under Nasdaq Rules. The offering includes 986,000 shares of common stock and warrants at $9.84 per share, with an acceleration clause tied to positive Phase 2 Alzheimer's Disease program data. The gross proceeds are around $9.7 million before fees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
News
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
Rhea-AI Summary
INmune Bio, Inc. announces the successful 24-month stability validation of XPro™, a key step towards Phase III readiness and commercial supply chain development. The company also developed a novel immunogenicity assay for XPro™, addressing potential false positive readings. The 24-month stability data allows for the use of a global distribution system, essential for future Phase III and commercial applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.56%
Tags
clinical trial
-
News
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
Rhea-AI Summary
INmune Bio Inc. raised approximately $4.8 million in gross proceeds through a registered direct offering, with officers, employees, and directors purchasing about 20% of the offering. The Company entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above-market warrant exercise prices. The offering was priced at $8.32 per share, with warrants giving investors the right to purchase additional shares at $9.152. The gross proceeds are expected to be $4.8 million before expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.94%
Tags
offering
News
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Rhea-AI Summary
INmune Bio, Inc. presents data on the use of INB03, a dominant-negative TNF inhibitor, in high-risk breast cancer at AACR. INB03 shows promising results in decreasing tumor growth, promoting T cell infiltration, and reprogramming macrophages. The study highlights the potential of INB03 to enhance immune response and prevent metastasis in TNBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
News
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
Rhea-AI Summary
INmune Bio Inc. announces financial results for 2023, highlighting progress in AD02 program for Early Alzheimer's Disease and INB03 cancer platform. The company reports positive data on XPro™ treatment for AD patients and improvements in T-DXd potency for HER2+ breast cancer. INKmune™ platform shows promising results in mCRPC trials, with plans for expansion into other solid tumors. Mark Lowdell's research on NK cell dysfunction and its role in carcinogenesis is also noted. Upcoming milestones include Phase II trials for XPro™ in neuroinflammation and Treatment-Resistant Depression, as well as progress in mCRPC trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
News
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
Rhea-AI Summary
INmune Bio Inc. (NASDAQ: INMB) will host a conference call to discuss its fourth-quarter results and provide a corporate update on March 28, 2024, at 4:30 PM Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
conferences earnings
News
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
Rhea-AI Summary
INmune Bio Inc. (NASDAQ: INMB) announces that its Chief Scientific Officer, Dr. Mark Lowdell, has been awarded the Career Achievement Award in Cell and Gene Therapy by the International Society for Cell & Gene Therapy (ISCT). Dr. Lowdell's 30+ years of expertise in translational immunotherapy have led to the development of innovative cell-based therapies, including INmune Bio's INKmune cancer immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
News
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
Rhea-AI Summary
INmune Bio, Inc. (INMB) reports significant improvements in brainwaves of Alzheimer's Disease patients treated with XPro™ therapy. Patients showed increased Alpha wave frequency and power after 4 weeks of treatment, indicating potential cognitive benefits. The positive results support previous findings of reduced inflammation and improved brain function with XPro™. The use of EEG as a biomarker for brain function in Alzheimer's research is groundbreaking.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
none
-
News
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
INmune Bio, Inc. (NASDAQ: INMB) will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company focuses on targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with XProTM. The presentation will be held virtually on February 14, 2024, by the CEO, RJ Tesi, M.D., and CFO, David Moss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
conferences
News
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
Rhea-AI Summary
INmune Bio, Inc. announces participation in Baird’s Biotech Discovery Series webcast to discuss ongoing Phase II trial for Early Alzheimer's disease and Phase I trial data, featuring key speakers and registration details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
conferences
Stock INMB logo
INmune Bio Inc

Nasdaq:INMB

INMB Rankings

#3758 Ranked by Market Cap
#2639 Ranked by Stock Gains
N/A Ranked by Dividends

INMB Stock Data

187.30M
11.74M
34.91%
13.83%
8.47%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boca Raton

About INMB

inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.